| Argomenti e Notizie sull'Osteoporosi con raccolte bibliografiche su 
|
a cura del Dott. C.Tarozzi Bologna |
|
| Ricerca nell'archivio di questo sito... ? | ||
|
Anastasilakis AD, Toulis KA, Polyzos SA, Terpos E.
RANKL inhibition for the management of patients with benign metabolic bone disorders.
Expert Opin Investig Drugs. 2009 Aug;18(8):1085-102. Review.
Blackwood J.
Denosumab, osteoporosis, and prevention of fractures.
N Engl J Med. 2009 Nov 26;361(22):2189; author reply 2190-1.
Blythe SL.
Denosumab, osteoporosis, and prevention of fractures.
N Engl J Med. 2009 Nov 26;361(22):2189-90; author reply 2190-1.
Burkiewicz JS, Scarpace SL, Bruce SP.
Denosumab in osteoporosis and oncology.
Ann Pharmacother. 2009 Sep;43(9):1445-55. Epub 2009 Jul 21. Review.
Burnett-Bowie SM.
Is twice-yearly denosumab beneficial in postmenopausal women with osteopenia but no history of fracture?
Nat Clin Pract Endocrinol Metab. 2008 Dec;4(12):660-1. Epub 2008 Nov 4.
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial.
Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
N Engl J Med. 2009 Aug 20;361(8):756-65. Epub 2009 Aug 11. Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914.
De Paula FJ, Rosen CJ.
Developing drugs to treat osteoporosis: lessons learned?
Expert Opin Pharmacother. 2010 Apr;11(5):867-9.
Deeks ED, Dhillon S.
Strontium ranelate: a review of its use in the treatment of postmenopausal osteoporosis.
Drugs. 2010 Apr 16;70(6):733-59.
Deodhar A, Dore RK, Mandel D, Schechtman J, Shergy W, Trapp R, Ory PA, Peterfy CG, Fuerst T, Wang H, Zhou L, Tsuji W, Newmark R.
Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients.
Arthritis Care Res (Hoboken). 2010 Apr;62(4):569-74.
RANKL inhibition for the management of patients with benign metabolic bone disorders.
Expert Opin Investig Drugs. 2009 Aug;18(8):1085-102. Review.
Denosumab, osteoporosis, and prevention of fractures.
N Engl J Med. 2009 Nov 26;361(22):2189; author reply 2190-1.
Denosumab, osteoporosis, and prevention of fractures.
N Engl J Med. 2009 Nov 26;361(22):2189-90; author reply 2190-1.
Denosumab in osteoporosis and oncology.
Ann Pharmacother. 2009 Sep;43(9):1445-55. Epub 2009 Jul 21. Review.
Is twice-yearly denosumab beneficial in postmenopausal women with osteopenia but no history of fracture?
Nat Clin Pract Endocrinol Metab. 2008 Dec;4(12):660-1. Epub 2008 Nov 4.
Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
N Engl J Med. 2009 Aug 20;361(8):756-65. Epub 2009 Aug 11. Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914.
Developing drugs to treat osteoporosis: lessons learned?
Expert Opin Pharmacother. 2010 Apr;11(5):867-9.
Strontium ranelate: a review of its use in the treatment of postmenopausal osteoporosis.
Drugs. 2010 Apr 16;70(6):733-59.
Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients.
Arthritis Care Res (Hoboken). 2010 Apr;62(4):569-74.
Doggrell SA.
Good clinical endpoints with denosumab in osteoporosis and cancer.
Expert Opin Pharmacother. 2009 Dec;10(17):2939-43.
Gallagher JC, Sai AJ.
Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis.
Maturitas. 2010 Apr;65(4):301-7. Epub 2010 Jan 29.
Hiligsmann M, Reginster JY.
Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.
Bone. 2010 Mar 18. [Epub ahead of print]
Kearbey JD, Gao W, Fisher SJ, Wu D, Miller DD, Dalton JT.
Effects of selective androgen receptor modulator (SARM) treatment in osteopenic female rats.
Pharm Res. 2009 Nov;26(11):2471-7. Epub 2009 Sep 1.
Kiechl S, Willeit J, Schett G.
Denosumab, osteoporosis, and prevention of fractures.
N Engl J Med. 2009 Nov 26;361(22):2188-9; author reply 2190-1.
Kyrgidis A.
Denosumab, osteoporosis, and prevention of fractures.
N Engl J Med. 2009 Nov 26;361(22):2189; author reply 2190-1.
Leibbrandt A, Penninger JM.
RANKL/RANK as key factors for osteoclast development and bone loss in arthropathies.
Adv Exp Med Biol. 2009;649:100-13. Review.
Lewiecki EM.
Denosumab for joints and bones.
Curr Rheumatol Rep. 2009 Jul;11(3):196-201. Review.
Lewiecki EM.
Denosumab update.
Curr Opin Rheumatol. 2009 Jul;21(4):369-73. Review.
Lewiecki EM.
Denosumab--an emerging treatment for postmenopausal osteoporosis.
Expert Opin Biol Ther. 2010 Mar;10(3):467-76. Review.
Pageau SC.
Denosumab.
MAbs. 2009 May;1(3):210-5. Epub 2009 May 29.
Good clinical endpoints with denosumab in osteoporosis and cancer.
Expert Opin Pharmacother. 2009 Dec;10(17):2939-43.
Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis.
Maturitas. 2010 Apr;65(4):301-7. Epub 2010 Jan 29.
Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.
Bone. 2010 Mar 18. [Epub ahead of print]
Effects of selective androgen receptor modulator (SARM) treatment in osteopenic female rats.
Pharm Res. 2009 Nov;26(11):2471-7. Epub 2009 Sep 1.
Denosumab, osteoporosis, and prevention of fractures.
N Engl J Med. 2009 Nov 26;361(22):2188-9; author reply 2190-1.
Denosumab, osteoporosis, and prevention of fractures.
N Engl J Med. 2009 Nov 26;361(22):2189; author reply 2190-1.
RANKL/RANK as key factors for osteoclast development and bone loss in arthropathies.
Adv Exp Med Biol. 2009;649:100-13. Review.
Denosumab for joints and bones.
Curr Rheumatol Rep. 2009 Jul;11(3):196-201. Review.
Denosumab update.
Curr Opin Rheumatol. 2009 Jul;21(4):369-73. Review.
Denosumab--an emerging treatment for postmenopausal osteoporosis.
Expert Opin Biol Ther. 2010 Mar;10(3):467-76. Review.
Denosumab.
MAbs. 2009 May;1(3):210-5. Epub 2009 May 29.
Podgorski I.
Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?
Future Med Chem. 2009 Apr 1;1(1):21-34.
Pérez-Castrillón JL, De Luis DA, Duenas-Laita A.
Are beta-blockers useful in the prevention of osteoporotic fractures?
Eur Rev Med Pharmacol Sci. 2009 May-Jun;13(3):157-62. Review.
Rossini M, Viapiana O, Gatti D, Adami S.
Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
Clin Ther. 2009 Jul;31(7):1497-510. Review.
Roux S.
New treatment targets in osteoporosis.
Joint Bone Spine. 2010 Apr 6. [Epub ahead of print]
Silverman SL.
New therapies for osteoporosis: zoledronic acid, bazedoxifene, and denosumab.
Curr Osteoporos Rep. 2009 Sep;7(3):91-5. Review.
Spivacow FR, Sarli M, Buttazzoni M.
[Treatment with bisphosphonates and atypical fractures].
Medicina (B Aires). 2009;69(6):612-8. Spanish.
Stepán J.
[Osteoporosis: whom, when and how to treat?].
Cas Lek Cesk. 2009;148(1):25-33. Review. Czech.
Tansey MG, Szymkowski DE.
The TNF superfamily in 2009: new pathways, new indications, and new drugs.
Drug Discov Today. 2009 Dec;14(23-24):1082-8. Epub 2009 Oct 28.
Toulis KA, Anastasilakis AD.
Erratum to: Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab.
Osteoporos Int. 2010 Feb 5. [Epub ahead of print]
Toulis KA, Anastasilakis AD.
Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab.
Osteoporos Int. 2009 Dec 15. [Epub ahead of print]
Törring O.
[Denosumab efficient against osteoporosis. A biological drug gives new possibilities to treat a public disease].
Lakartidningen. 2010 Mar 3-9;107(9):574-5. Swedish.
Uebelhart B, Rizzoli R.
[Osteoporosis].
Rev Med Suisse. 2010 Jan 13;6(231):56-60, 62. French.
Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?
Future Med Chem. 2009 Apr 1;1(1):21-34.
Are beta-blockers useful in the prevention of osteoporotic fractures?
Eur Rev Med Pharmacol Sci. 2009 May-Jun;13(3):157-62. Review.
Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
Clin Ther. 2009 Jul;31(7):1497-510. Review.
New treatment targets in osteoporosis.
Joint Bone Spine. 2010 Apr 6. [Epub ahead of print]
New therapies for osteoporosis: zoledronic acid, bazedoxifene, and denosumab.
Curr Osteoporos Rep. 2009 Sep;7(3):91-5. Review.
[Treatment with bisphosphonates and atypical fractures].
Medicina (B Aires). 2009;69(6):612-8. Spanish.
[Osteoporosis: whom, when and how to treat?].
Cas Lek Cesk. 2009;148(1):25-33. Review. Czech.
The TNF superfamily in 2009: new pathways, new indications, and new drugs.
Drug Discov Today. 2009 Dec;14(23-24):1082-8. Epub 2009 Oct 28.
Erratum to: Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab.
Osteoporos Int. 2010 Feb 5. [Epub ahead of print]
Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab.
Osteoporos Int. 2009 Dec 15. [Epub ahead of print]
[Denosumab efficient against osteoporosis. A biological drug gives new possibilities to treat a public disease].
Lakartidningen. 2010 Mar 3-9;107(9):574-5. Swedish.
[Osteoporosis].
Rev Med Suisse. 2010 Jan 13;6(231):56-60, 62. French.
questo sito aderisce ai principi HONCODE disclaimer